Purines: from premise to promise.

Area of Science:

• Pharmacology
• Neuroscience
• Drug Discovery

Background:

• Purinergic signaling, involving purines like ATP, plays crucial roles in physiological processes.
• Geoff Burnstock's foundational work established purinergic signaling as a significant area for therapeutic intervention.
• Despite extensive research, P1 receptor-targeted drug discovery has faced challenges in achieving pharmaceutical success.

Purpose of the Study:

• To review the progress and therapeutic potential of purinergic research, focusing on P1 and P2 receptors.
• To highlight promising therapeutic areas identified through P2 receptor research.
• To discuss the evolving landscape of purinergic drug discovery, including biotech industry involvement.

Main Methods:

• Review of existing literature on purinergic signaling and drug discovery efforts.
• Analysis of P1 and P2 receptor-mediated biological effects.
• Examination of data from transgenic knockout models to understand in vivo functions.
• Assessment of therapeutic applications in various disease models.

Main Results:

• P1 receptor-based medicinal chemistry has not met anticipated pharmaceutical success over 25 years.
• P2 receptors (P2X and P2Y families) show significant therapeutic potential.
• Key therapeutic areas identified for P2 receptor targeting include cystic fibrosis, chronic bronchitis, male contraception, and neurodegeneration.

Conclusions:

• Purinergic research, particularly targeting P2 receptors, offers substantial promise for novel drug development.
• The involvement of the biotech industry is fostering an environment conducive to nurturing the risks associated with 'first-in-field' purinergic therapeutics.
• Continued research into purinergic signaling pathways is essential for advancing therapeutic strategies.